Online inquiry

IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ325MR)

This product GTTS-WQ325MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD27 gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001242.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 939
UniProt ID P26842
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ325MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14056MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ2589MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 531
GTTS-WQ3206MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARGX-110
GTTS-WQ12354MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ5253MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ605MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ12922MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ3212MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW